Literature DB >> 17344883

Toll-free vaccines?

Arthur M Krieg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17344883     DOI： 10.1038/nbt0307-303

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

1.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

Review 2.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

3.  Vaccine-induced antibody isotypes are skewed by impaired CD4 T cell and invariant NKT cell effector responses in MyD88-deficient mice.

Authors:  Onyinye I Iweala; Donald W Smith; Kabir S Matharu; Isabel Sada-Ovalle; Deanna D Nguyen; Rosemarie H Dekruyff; Dale T Umetsu; Samuel M Behar; Cathryn R Nagler
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

Review 4.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

5.  A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection.

Authors:  Kejian Yang; Barbara J Whalen; Rebecca S Tirabassi; Liisa K Selin; Tatyana S Levchenko; Vladimir P Torchilin; Edward H Kislauskis; Dennis L Guberski
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

6.  Antigen-free adjuvant assists late effector CD4 T cells to transit to memory in lymphopenic hosts.

Authors:  F Betul Guloglu; Jason S Ellis; Xiaoxiao Wan; Mermagya Dhakal; Christine M Hoeman; Jason A Cascio; Habib Zaghouani
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

Review 7.  Toll-like receptor-4 modulation for cancer immunotherapy.

Authors:  Shanjana Awasthi
Journal:  Front Immunol       Date:  2014-07-25       Impact factor: 7.561

8.  Drug delivery-mediated control of RNA immunostimulation.

Authors:  David N Nguyen; Steve C-Y Chen; James Lu; Michael Goldberg; Phillip Kim; Andrew Sprague; Tatiana Novobrantseva; Jennifer Sherman; Svetlana Shulga-Morskaya; Antonin de Fougerolles; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

Review 9.  Multiple roles of toll-like receptor 4 in colorectal cancer.

Authors:  Dhanusha Yesudhas; Vijayakumar Gosu; Muhammad Ayaz Anwar; Sangdun Choi
Journal:  Front Immunol       Date:  2014-07-15       Impact factor: 7.561

10.  Immunogenicity and efficacy of a plasmid DNA rabies vaccine incorporating Myd88 as a genetic adjuvant.

Authors:  Padinjaremattathil Thankappan Ullas; Anita Desai; Shampur Narayan Madhusudana
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.